Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study-Reference-Cited by-同舟云学术

Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study

Published:2016-11-22 Issue:2 Volume:264 Page:268-276
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Planté-Bordeneuve Violaine,Gorram Farida,Salhi Hayet,Nordine Tarik,Ayache Samar S.,Le Corvoisier Philippe,Azoulay Daniel,Feray Cyrille,Damy Thibaud,Lefaucheur Jean-Pascal

Publisher

Springer Science and Business Media LLC

Subject

Clinical Neurology,Neurology

Link

http://link.springer.com/content/pdf/10.1007/s00415-016-8337-3.pdf

Reference24 articles.

1. Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M et al (2015) Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 66:2451–2466

2. Planté-Bordeneuve V, Said G (2011) Familial amyloid polyneuropathy. Lancet Neurol 10:1086–1097

3. Lefaucheur JP, Ng Wing Tin S, Kerschen P, Damy T, Planté-Bordeneuve V (2013) Neurophysiological markers of small fibre neuropathy in TTR-FAP mutation carriers. J Neurol 260:1497–1503

4. Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S et al (1991) Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 40:242–246

5. Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O et al (1993) Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 341:1113–1116

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T2-relaxometry in a large cohort of hereditary transthyretin amyloidosis with polyneuropathy;Amyloid;2024-09-02

2. Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review;Frontiers in Neurology;2024-09-02

3. Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study;Journal of the Formosan Medical Association;2024-09

4. Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin‐mediated amyloidosis with polyneuropathy;European Journal of Neurology;2024-07-10

5. Safety, Tolerability, and Outcomes of Tafamidis for the Treatment of Acquired Amyloid Neuropathy in Domino Liver Transplant Recipients;Neurology and Therapy;2024-05-10